Eriblin mesylate

【Product name】Halaven

[English common name]Eribulin

[Chinese common name]Eriblin mesylate

[English name]Eribulin Mesilate

[Chinese other name]Erebrin mesylate

[Indications] for the treatment of metastasis that has been treated with at least 2 chemotherapy regimensBreast cancerPatients, and the chemotherapy regimen should include an anthracycline or a taxane.

【Dosage】Eribulin mesylate was dissolved in a 5% by volume aqueous solution of ethanol at a concentration of 0.5 g/mL, usually at a dose of 21 days (1 day): 1.4 mg at 1 d and 8 d M2, intravenous injection lasted 2-5 min.

[Storage] From a microbiological point of view, the product should be used immediately unless the opening method eliminates the risk of microbial contamination. If not used immediately, the storage time and conditions in use are the responsibility of the user.
If HALAVEN is not used immediately as an undiluted solution in a syringe, it should not be stored for more than 4 hours at 25 ° C and ambient light, or 24 hours at 2 ° C – 8 ° C.
A diluted solution of HALAVEN (0.018 mg / ml to 0.18 mg / ml eribulin in sodium chloride 9 mg / ml (0.9%)) should not be stored at 2 ° C – 8 ° C for more than 24 hours unless Dilution is carried out under controlled and effective aseptic conditions.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

Description

name

Attention: The internal data of table “81” is corrupted!

product

Attention: The internal data of table “82” is corrupted!

product manual

Click to view the eribulin injection of methanesulfonate

Click to view the Chinese product description of eribulin injection

Product information

Click to view the product information of Aibubrin injection

Click to view the product specifications of eribulin injection

Related products

  • Breast cancer

    Ixapilone

    【Product name】Ixempra

    [English common name]Ixabepilone

    [Chinese common name]Ixapilone

    [English name]Ipsapironum

    [Chinese other name]1-dioxide

    [Indications] IXEMPRA combined with capecitabine for the treatment of metastatic or local advancedBreast cancerPatients who are resistant to anthracyclines and taxanes, or whose cancers have taxane resistance and are further contraindicated for their anthracycline treatment. Anthracycline resistance is defined as the progressive metastatic environment during treatment or within 6 months or within 3 months of the adjuvant treatment group. Taxane resistance is defined as progression at treatment or within 12 months of adjuvant therapy or at 4 months in a metastatic environment.
    IXEMPRA is indicated for the treatment of advanced breast cancer anthracyclines, taxanes and capecitabine in patients with metastatic or local monotherapy tumor-resistant or refractory patients.

    [Usage and Dosage] The recommended dose of IXEMPRA is 40 mg / m 2 and intravenous administration for 3 hours every 3 weeks. The dose of a patient with a body surface area (BSA) greater than 2.2 m2 should be calculated according to 2.2 m2.

    [Storage] The IXEMPRA kit must be stored in a refrigerator at 2 ° C to 8 ° C (36 ° F to 46 ° F). Keep the original packaging until it is used to prevent light.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer

    Lapatinib

    【Product name】Tykerb

    [English common name]Lapatinib

    [Chinese common name]Lapatinib

    [English name]4-Quinazolinamine, lapatinib ditosylate monohydrate, GSK572016

    [Chinese other name]Lapatinib base, lapatinib dimethanesulfonate intermediate, lapatinib monomer

    [Indications] TYKERB lapatinib is used in combination with capecitabine for the treatment of ErbB-2 overexpression, and has previously received advanced or metastatic treatment including anthracyclines, paclitaxel, and trastuzumab (Herceptin).Breast cancer.

    [Usage and Dosage] The recommended dose is 1 250 mg once a day, taken on the 1st to 21st day, combined with capecitabine 2 000 mg/d, and taken in 1 to 14 days. Lapatinib should be taken once a day. It is not recommended to take it in divided doses. Take 1 h before meals or 2 h after meals. If one dose is missed, the dose will not be doubled on the second day. Pregnancy level D, pregnant women are banned. It is unclear whether milk secretion is passed, and lactating women should stop breastfeeding. There were no significant differences between the elderly and young patients. Patients with severe kidney damage and dialysis have not been clinically tested, and patients with moderate to severe liver damage should be given a dose reduction.

    [Storage] Do not store above 30oC.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer , Renal cell carcinoma (RCC)

    Sorafenib

    【Product name】NEXAVAR

    [English common name]Sorafenib

    [Chinese common name]Sorafenib

    [English name]

    [Chinese other name]Solafini, sorafini monomer

    [indications]
    Sorafenib: TYKERB lapatinib is used in combination with capecitabine to treat ErbB-2 overexpression and has previously received advanced or metastatic treatments including anthracyclines, paclitaxel, and trastuzumab (Herceptin). SexBreast cancer.
    Sorafenib tosylate tablets: treatment of advanced surgeryRenal cell carcinoma.
    Nexavar (Sorafenib): Sorafenib has been approved for the treatment of advanced renal cell carcinoma (the most common type of kidney cancer). In addition, there are currently nearly 50 clinical trials in the world that use sorafenib to treat a variety of other cancers.

    【Dosage】
    Sorafenib: The recommended dose is 1250 mg, once a day, on days 1 to 21, with capecitabine 2000 mg/d, and on the first to 14 days in 2 divided doses. Lapatinib should be taken once a day. It is not recommended to take it in divided doses. Take 1 h before meals or 2 h after meals. If one dose is missed, the dose will not be doubled on the second day. Pregnancy level D, pregnant women are banned. It is unclear whether milk secretion is passed, and lactating women should stop breastfeeding. There were no significant differences between the elderly and young patients. Patients with severe kidney damage and dialysis have not been clinically tested, and patients with moderate to severe liver damage should be given a dose reduction.
    Sorafenib tosylate tablets:
    Recommended Dosage: It is recommended to take sorafenib for 0.4 g (2 x 0.2 g) each time, twice daily, on an empty stomach or with a low-fat, medium-fat diet.
    How to use: Oral, swallow with a cup of warm water.
    Treatment time: The treatment should be continued until the patient is unable to clinically benefit or tolerate the toxic reaction.
    Nexavar (Sorafenib): Patients should read the product instructions and patient instructions carefully before taking the drug. Patients should be advised to take effective contraception during the medication and to try to conceive after at least 2 weeks of discontinuation. Inform patients to take the medicine on an empty stomach. If the patient forgets to take the medicine, there is no need to increase the dose for the next dose. When the patient has a rash on the hands and feet during the medication, he should contact the doctor for treatment accordingly.

    [Storage]
    Sorafenib tosylate tablets: Store at a temperature below 25 ° C. Keep the drug out of the reach of children.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer

    Pertuzumab

    【Product name】Perjeta

    [English common name]Pertuzumab

    [Chinese common name]Pertuzumab

    [English name]Ertuzumab [INN], Omnitarg, rhuMAb 2C4

    [Chinese other name]

    [Indications] PERJETA is a HER2/neu receptor antagonist that should be combined with trastuzumab and docetaxel. The treatment population is: no previous anti-HER2 treatment or chemotherapy. HER2+ metastaticBreast cancerpatient.

    【Dosage】
    (1) Intravenous infusion only. Do not administer intravenous bolus or bolus.
    (2) The initial dose was 840 mg, and the intravenous infusion was completed over 60 minutes. Thereafter, 420 mg every 3 weeks, intravenous infusion over a period of 30 to 60 minutes.

    [Storage]Protected from light and stored in the refrigerator at 2 ° C to 8 ° C (36 ° F to 46 ° F).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.